Generic Lialda Availability
LIALDA (mesalamine - tablet, delayed release;oral)
Has a generic version of Lialda been approved?
No. There is currently no therapeutically equivalent version of Lialda available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lialda. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Mesalazine controlled release oral pharmaceutical compositions
Issued: August 10, 2004
Inventor(s): Roberto; Villa & Massimo; Pedrani & Mauro; Ajani & Lorenzo; Fossati
Assignee(s): Cosmo S.p.A.
Controlled-release oral pharmaceutical compositions containing as active ingredient 5-amino-salicylic acid, comprising: a) an inner lipophilic matrix consisting of substances with a melting point below 90° C. in which the active ingredient is at least partly inglobated; b) an outer hydrophilic matrix in which the lipophilic matrix is dispersed; c) optionally other excipients.Patent expiration dates:
- June 8, 2020✓
- June 8, 2020
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- July 14, 2014 - MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
- Lialda Consumer Information (Drugs.com)
- Lialda delayed-release tablets Consumer Information (Wolters Kluwer)
- Lialda Consumer Information (Cerner Multum)
- Lialda Advanced Consumer Information (Micromedex®)
- Mesalamine controlled-release capsules Consumer Information (Wolters Kluwer)
- Mesalamine delayed-release capsules Consumer Information (Wolters Kluwer)
- Mesalamine delayed-release tablets Consumer Information (Wolters Kluwer)
- Mesalamine enema Consumer Information (Wolters Kluwer)
- Mesalamine extended-release capsules Consumer Information (Wolters Kluwer)
- Mesalamine suppositories Consumer Information (Wolters Kluwer)
- Mesalamine Consumer Information (Cerner Multum)
- Mesalamine rectal Consumer Information (Cerner Multum)
- SfRowasa rectal Consumer Information (Cerner Multum)
- Mesalamine Advanced Consumer Information (Micromedex®)
- Mesalamine Rectal Advanced Consumer Information (Micromedex®)
- SfRowasa Advanced Consumer Information (Micromedex®)
- Mesalamine AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|